Ann: Litigation Update, page-58

Ahhhhaaaaahaa, aaahhhhhaaaa ,
I just read the allegations. Seriously!

Allegations
The consolidated class action alleges that Mesoblast breached its continuous disclosure obligations and engaged in misleading and deceptive conduct by:
1.misrepresenting the efficacy and potential benefit of treating patients suffering from SR-aGVHD or COVID-19 ARDS with R-L;

2.misrepresenting the significance of trial results, including the relevance of earlier studies, post hoc analysis and data collated for controls and contrast;

3.not disclosing to the market material information, including the deficiencies in the study design and statistics presented;

4. and not disclosing all information required for investors to be able to reasonably assess the likelihood of whether R-L would be shown to be effective in treating SR-aGVHD or COVID-19 ARDS, and then be commercialised on that basis.


DYOR <--------------------------<---------------------------

https://clinicaltrials.gov/study/NCT02336230?cond=Remestemcel-L&rank=9&tab=history

You can even see the updates side by side. 2018 and 2020
https://classic.clinicaltrials.gov/ct2/history/NCT02336230?B=9&A=5&C=merged#StudyPageTop

Two whole minutes of my time